Stay updated on Nivolumab and Plinabulin in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Plinabulin in NSCLC Clinical Trial page.

Latest updates to the Nivolumab and Plinabulin in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record for a Phase 1 study combining nivolumab and plinabulin in metastatic non-small cell lung cancer is displayed, with study design, eligibility, outcomes, and record dates. The study is completed and no longer recruiting participants.SummaryDifference45%

- Check19 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2 on the study-record error page.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide banner announces NIH website updates and a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer’s ClinicalTrials.gov site revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now renders a 403 Forbidden error with the 403 header and navigation elements (including Home and a Revision: v3.7.0 line). A large set of study-related terms and identifiers was removed from the page content.SummaryDifference18%

Stay in the know with updates to Nivolumab and Plinabulin in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Plinabulin in NSCLC Clinical Trial page.